Stock Details
AZN is AstraZeneca PLC's stock. Stock exchange NasdaqGS (Currency USD). Average price in 50 days is 64.75$. Average daily volumn in 3 months 7.06M. Market cap 206.05B

Stock symbol : AZN. Exchange : NasdaqGS. Currency : USD
Lastest price : 66.49$. Total volume : 7.01M. Market state PRE
Click reload if you want to check the lastest price on market!!!

AstraZeneca PLC (AZN)
Last Price

Previous Close65.51
Day Range65.60-66.64
Bid0.00 x 800
Ask0.00 x 1.3k
Average Volume7.06M
Market Cap206.05B
52 Week Range53.63-71.70
Trailing P/EN/A
Foward P/E17.41
Dividend (Yield %)2.18%
Ex-Dividend Date2022-02-24

Financial Details

According to AstraZeneca PLC's financial reports the company's revenue in 2021 were 37.42B an increase( +42.31%) over the years 2020 revenue that were of 26.62B. In 2021 the company's total earnings were 112M while total earnings in 2020 were 3.2B(-96.27%).

Loading ...


AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolis... m diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Market Cap:
Total Assets:
Total Cash:

News about "AstraZeneca PLC"


AstraZeneca PLC ADR rises Wednesday, outperforms market

Source from : MarketWatch - 21 hours ago

The AstraZeneca PLC ADR rose 1.50% to $66.49 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the ...See details»


AE Wealth Management LLC Has $1.07 Million Holdings in AstraZeneca PLC (NASDAQ:AZN)

Source from : Defense World - 9 hours ago

AE Wealth Management LLC lessened its stake in shares of AstraZeneca PLC (NASDAQ:AZN โ€“ Get Rating) by 63.1% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange ...See details»


China Allows AstraZeneca's COVID Preventive Drug in Southern City

Source from : Voice of America - 1 days ago

China allows early use of new medical products in the special zone in Qionghai city as a part of several preferential policies granted to the area to promote medical services to visitors from both ...See details»

This is to seal it as AstraZeneca PLC (AZN) shares are up 22.15% from its 52-week low

Source from : investchronicle - 1 days ago

For the readers interested in the stock health of AstraZeneca PLC (AZN). It is currently valued at $65.51. When the transactions were called off in the previous session, Stock hit the highs of $65.53, ...See details»


Is it a Good Move to Acquire AstraZeneca (AZN) Shares?

Source from : Yahoo! Sports - 2 days ago

Carillon Tower Advisers, an investment management firm, published its โ€œCarillon Eagle Growth & Income Fundโ€ first quarter 2022 investor letter โ€“ a copy of which can be downloaded here. The Carillon ...See details»


Canada To Throw Out 13.6 Mln AstraZeneca Vaccine Doses

Source from : Nasdaq - 21 hours ago

Canada plans to throw out around 13.6 million doses of the Oxford-AstraZeneca Covid-19 vaccine as it could not find any takers for the vaccine neither at home or abroad. Canada had signed a contract ...See details»


AstraZeneca (AZN) to Buy TeneoTwo, Boost Hematology Pipeline

Source from : YAHOO!Finance - 2 days ago

AstraZeneca's (AZN) acquisition of TeneoTwo is set to add an early-stage T-cell engager to AZN's pipeline. The transaction is likely to close by third-quarter 2022.See details»


AstraZeneca PLC (NASDAQ:AZN) Stake Increased by Wedbush Securities Inc.

Source from : Defense World - 5 days ago

Wedbush Securities Inc. increased its stake in AstraZeneca PLC (NASDAQ:AZN โ€“ Get Rating) by 5.9% in the first quarter, according to the company in its most recent disclosure with the Securities and ...See details»

AstraZeneca to Buy TeneoTwo for Up to $1.27 Bln

Source from : MarketWatch - 2 days ago

By Ian Walker AstraZeneca PLC said Tuesday that it is buying TeneoTwo, Inc. for up to $1.27 billion in a deal that strengthens its haematological ...See details»

Big Teneo: Astrazeneca to buy Teneotwo in a deal worth up to $1.27B

Source from : BioWorld - 1 days ago

To build on its hematology pipeline in treating blood cancers, Astrazeneca plc is acquiring Teneotwo Inc. in a deal that could reach $1.27 billion. Teneotwo is part of Ancora Biotech LLC, which has ...See details»


Oxford Biomedica Inks New Three Year Deal To Make AstraZeneca's COVID-19 Vaccine

Source from : YAHOO!Finance - 6 days ago

Oxford Biomedica plc (OTC: OXBDF) signed a new three-year agreement to potentially make AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine beyond 2022. The new agreement represents an expansion of the ...See details»


S.Korea authorises AstraZeneca COVID therapy Evusheld for vulnerable people

Source from : Reuters - 7 days ago

South Korea on Thursday authorised AstraZeneca PLC's antibody-based therapy for preventing COVID-19 infection in people with a poor immune response, increasing its options as it works to ease the ...See details»

AstraZeneca to acquire blood cancer drug maker TeneoTwo for $100M upfront

Source from : Seeking Alpha - 2 days ago

AstraZeneca (AZN) is acquiring U.S.-based blood cancer drug makerย TeneoTwo forย $100M upfront plusย milestone payments.The British pharma giant will acquireย all outstanding ...See details»


What You Need To Know About AstraZeneca PLC's (LON:AZN) Investor Composition

Source from : Yahoo Style Australia - 8 days ago

The big shareholder groups in AstraZeneca PLC ( LON:AZN ) have power over the company. Insiders often own a large ...See details»